Frontlight ResearchEarly access
Sjögren's disease trials in Serbia
2 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Belgrade
- Age
- 18 years and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - Phase 3Taking peopleA Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- Where
- Belgrade, Kragujevac, Novi Sad
- Age
- 18 years and over
- People
- 844 worldwide
- Run by
- Amgen
See details and how to joinNCT06747949 · EU 2024-517513-32-00